Sahil Parikh, MD, talked to Cardiovascular Business about growing trends related to the treatment of critical lower limb ischemia. "We are getting better and better at saving their limbs, but we are not better at saving their lives," he said. 

The company's most well-known product within the industry is the CorPath GRX System, a second-generation robotics solution used by interventional cardiologists during PCI and other interventional procedures.

The single-dose gene therapy can help patients reduce their risk of bleeding events and discontinue factor IX prophylaxis therapy.

Nirmatrelvir-ritonavir, sold by Pfizer under the name Paxlovid, is commonly prescribed to treat COVID-19. When treating some heart patients, however, physicians may want to consider an alternative approach.

The FDA has had a busy month, overseeing the recall of nearly 88,000 implantable cardiac devices, juggling the continued rise of monkeypox cases in the United States and maintaining an active Breakthrough Devices program. This rundown covers some of the agency's biggest moves during that time. 

The new hydrogel material was designed to immediately conform to the patient's body and create a barrier.

Catch up on several recent FDA announcements, including an update on the agency's response to the COVID-19 pandemic. 

These recommendations, the group emphasized, do not include patients with a history of CVD or those who are already taking aspirin for another reason.